Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that γδ T cells in the skin contribute to wound healing after vaccinia virus infection by promoting cytokine and growth factor induction, without affecting virus replication control.

This study reports that telogen effluvium, a reversible hair loss condition following COVID-19, is influenced by factors like stress and inflammation, but appropriate dermatological treatment can aid recovery, as highlighted by a clinical case example.

In this study, researchers observed an increased incidence of pattern hair loss and telogen effluvium among COVID-19 patients, potentially linked to psychological stress, systemic inflammation, and oxidative stress, with reduced anagenic expression of proteoglycans suggested as a mediating mechanism.

This study found that acute stress can cause rapid hair loss by triggering necrosis in hair follicle cells and initiating autoimmunity, revealing a mechanism where stress-induced nerve activity leads to tissue damage and immune system activation.

This review discusses potential therapeutic options for frontal fibrosing alopecia by exploring distinct signaling pathways and cellular players, but reports no new clinical findings and emphasizes the need for further trials.

This review discusses the various triggers and diagnostic challenges in determining the cause of telogen effluvium-related hair loss, without providing new clinical results.

This study suggests that COVID-19 infection may trigger telogen effluvium, a condition of hair shedding, though medication side effects and pandemic-related stress cannot be excluded as contributing factors.

This article discusses how metabolic imbalances can trigger telogen effluvium by causing hair follicles to prematurely enter the shedding phase, and includes no new research findings.

This case study reports on a 4-year-old girl who developed telogen effluvium, a type of hair loss, after experiencing anaphylactic reactions to cow's milk. The authors highlight this as the first documentation of anaphylaxis potentially triggering telogen effluvium due to physiologic stress.

This study found that pediatric telogen effluvium in the US has varying triggers and management outcomes, with emotional stress and acute illness being the most common triggers.

This review consolidates the opinions of top Canadian dermatologists on managing telogen effluvium, highlighting the importance of proper diagnosis, identifying triggers, and patient education.

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

This review describes the diagnosis and management challenges of telogen effluvium, a type of hair loss triggered by physiological stress, and summarizes current understanding of its mechanisms and treatments while recommending future research directions.

This study found that telogen effluvium, a type of hair loss, was prevalent among 24% of COVID-19 patients, likely triggered by stress and medication related to the illness.

This review discusses different types of telogen effluvium, highlighting that most cases seen by dermatologists are autoimmune-related, with stress as a triggering factor, and reports no new clinical findings.

This case report describes a 2-year-old boy in critical condition who developed anagen effluvium, possibly due to hypotension and hypoxia triggering hair follicle apoptosis.

In this study, researchers linked SARS-CoV-2 infection to telogen effluvium in some COVID-19 patients by observing the accumulation of viral proteins in hair follicle cells, which may trigger stress responses and cell death, suggesting hair follicles as a potential target in COVID-19.

In this study, telogen effluvium is characterized as a common condition in women involving sudden hair shedding due to hair follicles prematurely entering the telogen phase, with potential triggers including fever, childbirth, and stress.

This case report describes post-COVID-19 telogen effluvium in a 39-year-old patient, suggesting that COVID-19 may trigger significant hair loss as a late symptom.

This multicenter study found that hair and nail disorders, particularly telogen effluvium, commonly developed in patients after severe COVID-19 infection.

COVID-19 and related stress may increase hair loss known as Telogen effluvium.

This case report describes an 85-year-old woman who developed localized telogen effluvium, a form of temporary hair loss, three months after Mohs micrographic surgery for basal cell carcinoma on her scalp, with complete hair regrowth achieved through minoxidil therapy within ten months.

This review addresses the causes, mechanisms, and treatment options for the most common non-scarring alopecias in females, including telogen effluvium, alopecia areata, and female pattern hair loss.

This review covers medication-induced telogen effluvium with a focus on systemic retinoids, antifungal agents, and psychotropic medications, and reports no new clinical results.

This review discusses telogen effluvium, including its causes, symptoms, diagnostic methods, and treatment strategies, without presenting new clinical findings.

This narrative review found that Telogen Effluvium significantly affects women in Brazil due to its psychological impact and limited access to treatment, exacerbated by economic and healthcare disparities.

This review discusses post-COVID hair loss, attributing it to potential pathogenic factors like cytokines and viral effects, and suggests that full recovery without specific treatment is expected.

This correspondence outlines a research aim to evaluate the usefulness of laboratory testing for telogen effluvium to assist in forming evidence-based treatment guidelines, though results are not provided in the abstract.

This review discusses telogen effluvium, a common form of hair loss, and reports no new clinical results; the authors outline possible causes, typical prognosis, and management strategies.

This article discusses telogen effluvium in women, its causes, and typical diagnostic methods, but reports no new research findings on clinical outcomes or treatments.